Compare Amphastar Pharmaceuticals Inc (AMPH) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs VanEck Junior Gold Miners — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while VanEck Junior Gold Miners trades at $120.97. The key difference: VanEck Junior Gold Miners is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | GDXJ | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $30.81 | $156.19 |
52-Week Low | $16.87 | $71.22 |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
GDXJ (VanEck Junior Gold Miners ETF) trades at $117.57, up 7.47% in the last 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The ETF shows strong momentum with ADX indicating a trending market, though RSI levels suggest potential overbought conditions. Recent institutional activity includes Amundi reducing its stake by 50.5% in the latest quarter (SEC Form 13F filing, August 2026).
The outlook for GDXJ is mixed—bullish technical trends conflict with bearish sentiment from oscillators and institutional selling. Key risks include gold price volatility and Federal Reserve policy impacts. Investment opportunity hinges on gold market strength, but caution is warranted given overbought signals and recent underperformance versus peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
